Shares of Editas Medicine, Inc. (EDIT) are climbing more than 28 percent on Wednesday morning trade after the company reported narrower net loss for the fourth quarter, compared to the prior year.
The quarterly loss was $18.87 million or $0.23 per share, narrower than $60.74 million or $0.88 per share last year. Analysts were looking for loss of $0.54 per share.
Collaboration and other research and development revenues surged to $60.05 million from $6.54 million in the prior year.
In the adolescent cohort of the Ruby trial, the company has initiated enrollment.
Currently, shares are at $11.39, up 28.53 percent from the previous close of $8.86 on a volume of 3,471,271.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.